Can-Fite BioPharma (CANF) Share-based Compensation (2013 - 2026)

Can-Fite BioPharma (CANF) has 12 years of Share-based Compensation data on file, last reported at $204465.0 in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 99.86% year-over-year to $204465.0; the trailing twelve-month figure through Jun 2026 stood at $204465.0 (down 99.86% YoY), and the FY2025 full-year result was $340000.0, down 6.08% from the prior year.
• Share-based Compensation was $204465.0 for Q2 2026 at Can-Fite BioPharma, up from $49533.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $148.8 million in Q2 2025 to a low of $41610.0 in Q4 2024.
• A 5-year average of $45.7 million and a median of $27.0 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 11739986.96% in 2022 and sank 99.95% in 2024, its largest moves.
• Can-Fite BioPharma's Share-based Compensation stood at $27.0 million in 2022, then soared by 205.45% to $82.5 million in 2023, then sank by 99.95% to $41610.0 in 2024, then climbed by 19.04% to $49533.0 in 2025, then surged by 312.79% to $204465.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $204465.0 in Q2 2026, $49533.0 in Q4 2025, and $148.8 million in Q2 2025.